December 15, 2020

Company name: Modalis Therapeutics Corporation
Stock exchange listing: Tokyo Stock Exchange
Code number: 4883
URL: https://www.modalistx.com/en/
Representative: Haruhiko Morita

Addition of MDL-104 to Our Internal Pipeline

Modalis Therapeutics Corporation (hereinafter the "Company") announces the addition of investigational asset MDL-104 to their internal pipeline.


The target indication of MDL-104 belongs to the area of neurodegenerative diseases. The name of the specific indication remains undisclosed for competitive reasons until the filed patents are published.

While MDL-104, which the Company has committed to develop as an internal pipeline, is in the early stages of development, we have received multiple requests for licensing from several major domestic and overseas pharmaceutical companies. As we are still in the process of intensive negotiations, the timing of the license agreement is yet to be determined but is expected to be in 2021. There will be no impact on our business results for the current fiscal year.

In addition to the filing of a patent application, an evaluation of feasibility, which is required before the Company decides to introduce new products to the internal pipeline, was approved by the Board of Directors today.

With the addition of MDL-104, the Company now has three products in their internal pipeline, and together with the five products in their collaborative pipeline, now has a total of eight products in development.

Of these, two new products, MDL-206 and MDL-104, will be added to the pipeline in 2020. Additionally, two products, MDL-101 and MDL-104, are currently under negotiation for licensing.



*1: We have adopted a strategy of withholding specific indications until the patent application is published for competitive reasons.
*2: MDC1A=Merosin-deficient congenital muscular dystrophy type 1A